Jafron Biomedical Co

Jafron Biomedical Co Net Debt / EBITDA

The Net Debt to EBITDA of Jafron Biomedical Co (300529.SZ) as of Nov 13, 2026 is 1.60. In the previous year, Net Debt to EBITDA was -1.01 — a change of -258.10% (higher).

Net Debt / EBITDA

1.60

YoY

-258.10%

Last updated:

Net Debt to EBITDA of Jafron Biomedical Co is 2025 1.60 . Net Debt to EBITDA of Jafron Biomedical Co was 2024 -1.01 . It decreases by -258.10% higher compared to the previous year.

The Jafron Biomedical Co Net Debt / EBITDA history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Net Debt / EBITDA
Date
Net Debt / EBITDA
Jan 1, 2018
-2.00 CNY
Jan 1, 2019
-1.75 CNY
Jan 1, 2020
-1.44 CNY
Jan 1, 2021
-1.07 CNY
Jan 1, 2022
-1.20 CNY
Jan 1, 2023
-1.93 CNY
Jan 1, 2024
-1.01 CNY
Jan 1, 2025
1.60 CNY
The Jafron Biomedical Co Net Debt / EBITDA history
YEARNet Debt / EBITDAYoY
1.60-258.10%
-1.01-47.46%
-1.93+60.68%
-1.20+11.92%
-1.07-25.69%
-1.44-17.49%
-1.75-12.73%
-2.00-26.74%
-2.73—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Jafron Biomedical Co Stock analysis

What does Jafron Biomedical Co do? Jafron Biomedical Co., Ltd. generates revenue through the research, development, production, and sale of hemoperfusion products and medical equipment. The company offers a range of items including disposable hemoperfusion devices, hemoperfusion machines, disposable bilirubin adsorbers, the DX-10 blood purification machine, suture needles, and resins bandage. These products are utilized for treating conditions such as uremia, poisoning, severe liver diseases, autoimmune diseases, and multisystem organ failure. The primary customers for these medical solutions are hospitals across China, where the company’s products are applied in more than 3000 hospitals within 31 provinces. As a China-based company, Jafron Biomedical Co., Ltd. focuses on the design, manufacture, and distribution of biological materials and medical equipment to support healthcare providers in these regions. The company operates from its headquarters in Zhuhai, Guangdong, and supports its operations with a workforce of 3,003 full-time employees. By engaging in the full lifecycle of its products from research to sale, the firm serves the medical sector with specialized equipment for blood purification and related therapeutic needs. Jafron Biomedical Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Jafron Biomedical Co stock

Net Debt to EBITDA of Jafron Biomedical Co is 1.60 in 2025.

Net Debt to EBITDA of Jafron Biomedical Co changed from -1.01 to 1.60, representing a -258.10% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Net Debt to EBITDA Jafron Biomedical Co since 2006 – with annual values, charts, and detailed analysis.

Net Debt/EBITDA measures how many years it would take to repay all debt using EBITDA. Lower ratios indicate stronger debt repayment capacity.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Net Debt to EBITDA's Jafron Biomedical Co with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Leverage — Jafron Biomedical Co

All Key Metrics — Jafron Biomedical Co